| Characteristics |
TDF Stopped |
| Yes (N=49) |
No (N=31) |
P value* |
| Age in years, median (IQR) |
55 (47-61) |
55 (47-61) |
0.7 |
| Weight in kg, median (IQR) |
75 (67-85) |
76 (64 -93) |
0.86 |
| Race, n (%) |
| Non Hispanic – White |
9 (18) |
6 (19) |
NA |
| Non Hispanic – Black |
38 (76) |
21 (68) |
| Other |
2 (4) |
4 (13) |
| Gender, n (%) |
| Female |
6 (12) |
7 (23) |
0.22 |
| Male |
43 (88) |
24 (77) |
| Baseline sCr in mg/dl, median (IQR)2 |
1 (1-1) |
1 (1-1) |
0.13 |
| Baseline GFR in ml/min, median (IQR)2 |
90 (70-107) |
87 (79-119) |
0.7 |
| sCr in mg/dl before HLA test, median (IQR)3 |
1 (1-2) |
1 (1-1) |
0.02 |
| GFR in ml/min before HLA test, median(IQR)3 |
67 (57-86) |
83 (66 -96) |
0.05 |
| sCr in mg/dl at HLA testing, median (IQR)4 |
1.7 (1.4-2) |
1.6 (1.3-2) |
0.26 |
| GFR in ml/min at HLA testing, median (IQR)4 |
52 (44-61) |
60 (50-74) |
0.06 |
| Recovered Renal Function, n (%) |
| Yes |
37 (76) |
17 (55) |
0.3 |
| No |
12 (24) |
14 (45) |
| Chronic Kidney Disease, n (%) |
| Yes |
8 (16) |
2 (6) |
0.3 |
| No |
41 (84) |
29 (94) |
| HCV Antibody status, n (%) |
| Positive |
12 (24) |
8 (26) |
0.89 |
| Negative |
37 (76) |
23 (74) |
| Diabetes Mellitus, n (%) |
| Yes |
9 (18) |
3 (10) |
0.35 |
| No |
40 (82) |
28 (90) |
| Hypertension, n (%) |
| Yes |
23 (47) |
12 (39) |
0.46 |
| No |
26 (53) |
19 (61) |
| Nephrotoxic Drugs, n (%) |
| Yes |
26 (53) |
16 (52) |
0.9 |
| No |
23 (47) |
15 (48) |
| HIV-1 PVL at HLA test, n (%) |
| ≥ 75 log10 copies/ml |
10 (21) |
9 (31) |
0.31 |
| < 75 log10 copies/ml |
38 (79) |
20 (69) |
| CD4 cell count at HLA test, n (%) |
| ≤ 200 cells/uL |
9 (19) |
7 (24) |
0.6 |
| > 200 cells/uL |
38 (81) |
22 (76) |
|
